Compugen Ltd (NASDAQ:CGEN) reported encouraging data from their studies on COM701, COM902, and pembrolizumab in patients with ...
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...
Compugen (CGEN) has released an update. Compugen Ltd. has announced promising data on the anti-tumor activity and safety of its triple ...
Medical Xpress on MSN13d
Study finds eczema-linked protein helps ovarian cancer survive, suggesting potential for skin drug-based treatmentOvarian cancer is one of the most deadly cancers; 50% of patients die within five years of diagnosis. While immunotherapy drugs such as pembrolizumab, which target the PD-1 molecule, have demonstrated ...
Reports Q3 revenue $17.1M, consensus $17.86M. Compugen (CGEN) expects that its cash and cash related balances will be sufficient to fund its ...
The SITC posters will be available on ImCheck's corporate website after the poster sessions have been opened.
Keytruda (pembrolizumab) is a prescription drug ... Does Keytruda treat ovarian cancer or brain cancer such as glioblastoma? Currently, Keytruda isn’t used to treat ovarian cancer.
New study reveals how ovarian cancer shields itself from the immune system, opening doors to innovative immunotherapy methods ...
Study findings suggest the potential to repurpose a drug that is FDA-approved for treating asthma and eczema, to enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback